ReviewNature reviews. Drug discovery2010
Anti-virulence strategies to combat bacteria-mediated disease.
Review in Nature reviews. Drug discovery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 677 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
677 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Role of Virulence Factors in Neonatal Sepsis Caused by Enterobacterales: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Single- and Multiple-dose Pharmacokinetics, Excretion, Metabolism, and Safety of the Antivirulence Agent Fluorothiazinone in Healthy Adults.Pharmaceutical research · 2025Trial
- Indole decreases the virulence of enterotoxigenic Escherichia coli.World journal of microbiology & biotechnology · 2026Article
- Anthranilate ReducesAntibiotics (Basel, Switzerland) · 2026Article
- Beyond the gut microbe: Rethinking infection, microbiome harmony, and the one-health continuum.World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- Berberine Hydrochloride Attenuates Growth, Biofilm Formation, and Virulence Associated Phenotypes of Actinobacillus pleuropneumoniae Strain APP-2023.Current microbiology · 2026Article
- 400 nm femtosecond laser irradiation eradicates mature MRSA biofilms and inhibits their formation via quorum sensing dysregulation.Scientific reports · 2026Article
- Article
- Stage V sporulation protein G as a global regulator of biofilm formation and virulence in Staphylococcus species: molecular mechanisms and therapeutic potential.World journal of microbiology & biotechnology · 2026Review
- Control Targets in Plant-Pathogenic Bacteria: From Growth-Essential Processes to Anti-Virulence Strategies and Candidate Targets inPlants (Basel, Switzerland) · 2026Review
- Article
- Collective fluctuations underlying nanobody inhibitory activity targetingbioRxiv : the preprint server for biology · 2026Article
- Article
- AnResearch square · 2026Article
- In Silico Prioritisation of Similarity-Selected Small Molecules Targeting the IsdB NEAT Domain ofInternational journal of molecular sciences · 2026Article
- Reduced efficacy of an anti-toxin vaccine from senescence-driven attenuation of toxin virulence.JCI insight · 2026Article
- Photochemical modification of two fluorene-based molecules with DNA intercalating and anti-methicillin resistant Staphylococcus aureus activity.The Journal of biological chemistry · 2026Article
- A chemical bactericide dioctyldiethylenetriamine (Xinjunan) exerts a non-lethal effect by inhibiting RpfG activity to regulate the quorum sensing system.PLoS pathogens · 2026Article
- Rethinking Microbial Chemical Ecology: Secondary Metabolites as Concentration-Dependent Signaling Hubs with Implications for Anti-Virulence Intervention.Microorganisms · 2026Review
- Silibinin Potentiates Antimicrobial Action and Reduces Staphyloxanthin inPharmaceuticals (Basel, Switzerland) · 2026Article
617 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotic resistance is one of the greatest challenges of the twenty-first century. However, the increasing understanding of bacterial pathogenesis and intercellular communication has revealed many potential strategies to develop novel drugs to treat bacteria-mediated disease. Interference with bacterial virulence and/or cell-to-cell signalling pathways is an especially compelling approach, as it is thought to apply less selective pressure for the development of bacterial resistance than traditional strategies, which are aimed at killing bacteria or preventing their growth. Here, we discuss the mechanisms of bacterial virulence and present promising anti-virulence strategies and compounds for the future treatment of bacterial infections.
Indexed as
Identifiers
20081869What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.